StreetAlpha.app
Home › Stocks › RGEN

Repligen Corp (RGEN)

Healthcare
Members
LATEST PRICE

Repligen makes bioprocessing equipment and consumables used to manufacture biological drugs. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (3 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in RGEN, 0% of them bullish and 100% bearish. In the past 30 days there were 7 dark pool prints.

Prices, price targets and earnings estimates for RGEN are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plans
AI Auto Pilots
Is RGEN in one of our four AI portfolios? Sign in free to see

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
4firms
3 Buy1 Hold0 Sell
Each firm's latest rating on RGEN in the past 90 days
Average 12-month target
Price targets for RGENThe average, highest and lowest analyst targets and the target chart are shown to AI Starter and AI Pro members.See plans
Latest rating changes
RBC CapitalTarget raised
Oct 28Buy
Canaccord GenuityMaintained
Oct 19Hold
BarclaysMaintained
Oct 7Buy
UBSMaintained
Sep 9Buy
Wells FargoMaintained
Jul 30Buy
DateFirmActionRatingPrice target
Oct 28RBC CapitalTarget raisedBuy
Oct 19Canaccord GenuityMaintainedHold
Oct 7BarclaysMaintainedBuy
Sep 9UBSMaintainedBuy
Jul 30Wells FargoMaintainedBuy
Loading…

Whale Options Flow

90D
Total alerts
1
Bullish
0
0%
Bearish
1
100%
Date span
Sep 21 – Sep 21
Loading…

Dark Pool

30D
Prints
7
Notional
Largest print
Loading…

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RGEN is in one of them and how their past RGEN trades turned out.

RGEN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RGEN in an article yet. Here's the latest on the wider market.

RGEN Congress Trades

All congress trades →
Trades, 12 months
4
Buys
1
25%
Sells
3
75%
People
2
Last filed Jul 1
Who traded RGEN · since 2022
Latest 5 filings of 12
$1K – $15KTraded May 22, 2026Filed Jul 1, 2026
$1K – $15KTraded Oct 31, 2025Filed Nov 21, 2025
$1K – $15KTraded Oct 30, 2025Filed Nov 21, 2025
$1K – $15KTraded Oct 30, 2025Filed Nov 21, 2025
$1K – $15KTraded Jul 22, 2025Filed Aug 13, 2025
PersonTypeAmountTradedFiledDelay
Donald J TrumpExecutive branchSell$1K – $15KMay 22, 2026Jul 1, 202640 d
Lisa McClainR · MISell$1K – $15KOct 31, 2025Nov 21, 202521 d
Lisa McClainR · MISell$1K – $15KOct 30, 2025Nov 21, 202522 d
Lisa McClainR · MIBuy$1K – $15KOct 30, 2025Nov 21, 202522 d
Lisa McClainR · MIBuy$1K – $15KJul 22, 2025Aug 13, 202522 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Repligen

Repligen is a life sciences company based in Waltham, Massachusetts, that makes equipment and consumables used to manufacture biological drugs. Its product lines cover filtration, chromatography, process analytics and proteins, including filters, tangential flow systems, columns that come already packed with resin, and fluid management parts. Its main customers are drug developers, contract manufacturers and other life science companies that make antibody-based drugs, vaccines, and cell and gene therapies.

Headquarters
Waltham, MA